AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01900340 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exendin 9-39
Description: IV exendin(9-39) infusion and intraduodenal administration of saline via feeding tube
Study NCT02715557 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relapse prevention program
Description: The relapse prevention program is an innovative computer-based coping skills educational program for adolescent substance abuse treatment completers.
Study NCT01555931 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levonorgestrel-releasing intrauterine system
Description: Placement within 48 hours of delivery
Study NCT01555931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine system
Description: Placement within 48 hours of delivery
Study NCT06250114 — intervention group
Intervention type: OTHER
Intervention: Retreatment
Description: manual k file, carrier based technique, Xrays, tooth build up, provisional and definitive crowns. Post if necessary will be placed
Study NCT06250114 — intervention group
Intervention type: OTHER
Intervention: extraction implant
Description: Flapless or flapped techniques, early, delayed and immediate implant insertions. Cement retrained restorations
Study NCT04604860 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fitness intervention
Description: Patients will follow exercise plans designed to promote physical activity (exercise and behavioral coaching).
Study NCT01510756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib 400mg orally twice daily will be administered for three cycles (1 cycle = 28 days). Subjects without significant toxicity or progressive disease may elect to continue treatment for a total of twelve cycles.
Study NCT05758454 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Caries and Obesity Prevention
Description: A culturally adapted oral health education intervention to prevent development of ECC and to improve parental oral health related knowledge and attitudes.
Study NCT00805532 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation treatment
Description: Behavioral Activation (BA) is a present-focused psychotherapy based on behavioral theory and principles of change, that aims to re-engage individuals with meaningful and pleasurable life activities by targeting and problem-solving patterns of avoidance. It is well-established as a treatment for depression and has been modified for the current study to address PTSD-related problems.
Study NCT03083717 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Collection of breath samples, followed by analysis of exhaled breath using nanomaterial-based sensors (NaNose)
Description: 2-3 liters of breath sample will be collected in chemically inert Mylar bags. The breath samples will then be immediately transferred from the Mylar bags to Tenax sorbent tubes using a dedicated pump. Tubes will be sealed and kept in 4˚C until NA-NOSE analysis.
Study NCT00805532 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Usual Care for PTSD (UC)-that is provided in the VA PTSD Specialty clinics. Actual clinical practice varies between sites and between providers within sites, as is typical of the VA health care system. Subjects assigned to Usual Care will be permitted to receive medical intervention (i.e., pharmacotherapy) and any additional psychotherapy deemed appropriate by the provider. They will also be offered a minimum of 6 sessions of individual therapy.
Study NCT00759772 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sc daily for 6 months
Study NCT00759772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriparatide
Description: 20 mcg sc daily for 6 months
Study NCT04241575 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Simple fibrosis scores and electronic reminder messages
Description: For patients in the intervention group, we will calculate the fibrosis scores. For patients with increased fibrosis scores, we will type the following pop-up message in our electronic clinical management system:~This patient has high Fibrosis-4 index (and/or AST-to-platelet ratio index) of xxx suggestive of significant liver fibrosis. Please consider referring the patient to the hepatology clinic or arranging further test such as FibroScan.~The reminder message will pop up when physicians see the patient at the clinic and use the electronic clinical management system. The message will remain active for one year. Although the message is entered manually at this stage, the arrangement mimics an automated computer system. If the study results are positive, the next step is to modify the system to automate the process.
Study NCT02978313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: anti-EGFR monoclonal antibody
Study NCT02978313 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: anti-EGFR monoclonal antibody
Study NCT02978313 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFOX6
Description: Oxaliplatin+LV5FU2
Study NCT02042066 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Omnispec model Vascuspec
Description: Energy Density: 0.09 - 0.1 mJ/mm2 Extracorporeal Shockwave Therapy
Study NCT03893292 — intervention group
Intervention type: PROCEDURE
Intervention: Total knee replacement
Description: Patients will undergo total knee replacement surgery.
Study NCT03893292 — intervention group
Intervention type: DEVICE
Intervention: COOLIEF
Description: The superior lateral genicular nerve, superior medial genicular nerve, and inferior medial geniculate nerve will be ablated.
Study NCT00469079 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine gum and lozenge
Description: Nicotine replacement
Study NCT00469079 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Taboka
Description: smokeless tobacco product
Study NCT00469079 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Camel Snus
Description: smokeless tobacco product
Study NCT03389243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metamizol
Description: in group M patients will receive pre-emptive analgesia using intravenous infusion of metamizol in a single dose of 1,25 gram
Study NCT03389243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol
Description: in group P patients will receive pre-emptive analgesia using intravenous infusion of metamizol in a single dose of 1,25 gram
Study NCT01063907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW-2478
Description: Administered Days 1, 4, 8 and 11 of a 21 day cycle
Study NCT01900340 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: IV saline infusion and intraduodenal administration of nutrients
Study NCT01900340 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exendin(9-39) plus ID nutrient
Description: Exendin(9-39) as intravenous infusion plus intraduodenal nutrient administration
Study NCT03122015 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic clown distraction
Description: The presence of the therapeutic clown, which can adapt his interventions of distraction to the state of health of the patient and the culture of the child, is a multimodal and multi sensorial distraction intervention and can have an impact on health status, procedures, family and multidisciplinary team members. The results of five studies evaluated the effects of distraction by the clown therapy demonstrate a decrease in pain and anxiety in children aged 2 to 17 years, as well as parental anxiety in painful procedures involving needles such as venipuncture.
Study NCT00752297 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Preservative-free Saline
Description: Subjects will receive five 0.1 mL intramuscular injections at the Day 0 Treatment Visit: two in each corrugator and one in the procerus muscle. The total treatment dose (sum of the five injections) to be administered will be 0.5 mL of the placebo (preservative-free saline).
Study NCT00752297 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mentor Purified Toxin
Description: All subjects will receive five 0.1 mL intramuscular injections (two in each corrugator and one in the procerus muscle) at each Treatment Visit. The total treatment dose (sum of the five injections) to be administered will be 30 U of PurTox. Subjects will have many Treatment Visits throughout the course of the three-year study.
Study NCT04293757 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rotational angiography
Description: Preprocedural imaging before ablation
Study NCT04290858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide
Description: Nitric Oxide (NO) will be delivered together with the standard of care for a period of 20-30 minutes 2 times per day for 14 consecutive days from time of enrollment. Targeted concentration will have a tidal oscillation between 100 and 300 ppm, in order to maintain an average inhaled concentration from 140 to 180 ppm. The gas will be delivered through a CPAP circuit ensuring an end-expiratory pressure between 2 and 10 cmH2O or trough a non-rebreathing mask without positive end expiratory pressure, depending on the clinical needs of the patient.
Study NCT02728856 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen Spray SPF50 Z15-034(BAY987516)
Description: Study staff will administer the control in one eye and a test sunscreen in the other eye according to the assigned randomization schedule.
Study NCT02728856 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shampoo Control
Description: Study staff will administer the control in one eye and a test sunscreen in the other eye according to the assigned randomization schedule.
Study NCT02728856 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen Spray SPF50 Z15-038(BAY987516)
Description: Study staff will administer the control in one eye and a test sunscreen in the other eye according to the assigned randomization schedule.
Study NCT03059966 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Microsurgery technique for root coverage
Description: Microsurgery technique for root coverage adapted for macrosurgery
Study NCT03059966 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Microsurgery technique for root coverage associated to EMD
Description: Microsurgery technique for root coverage adapted for macrosurgery associated to Enamel Matrix Derivative
Study NCT01063907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Administered on Days 1, 4, 8 and 11 of a 21 day cycle
Study NCT00927472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Malathion gel 0.5%
Description: Malathion gel 0.5% applied to scalp for 30 minutes. May be repeated in 1 week if head lice are still present.
Study NCT00927472 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Permethrin 1% rinse
Description: Permethrin 1% shampooed into scalp for 10 minutes. May be repeated in 1 week if head lice are still present.
Study NCT00038610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: 600 mg by mouth on days 1 - 14 for course 1, and 600 mg by mouth daily days 1-14 (or daily if tolerated with course 1) for courses 2, 4, 6, 8.
Study NCT00038610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 300 mg/m\^2 by vein every 12 hours for 6 doses days 1, 2, 3 (total dose 1800 mg/m\^2) for courses 1, 3, 5, 7.
Study NCT00038610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 50 mg/m\^2 by vein on day 4 after last dose of CTX for courses 1, 3, 5, 7.
Study NCT00038610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 2 mg by vein on day 4 and day 11 for courses 1, 3, 5, 7.
Study NCT00038610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 mg by vein or by mouth daily on days 1 - 4 and days 11 - 14 for courses 1, 3, 5, 7.
Study NCT00038610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 12 mg intrathecally (6 mg if via Ommaya reservoir) day 2 for courses 1, 3, 5, 7.~200 mg/m\^2 by vein over 2 hours followed by 800 mg/m\^2 over 22 hours on day 1 of courses 2, 4, 6, 8.
Study NCT00038610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 100 mg intrathecally day 7 for courses 1, 3, 5, 7.~3 gm/m2 by vein over 2 hrs every 12 hrs for 4 doses on days 2 and 3 for courses 2, 4, 6, 8.
Study NCT00038610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: 600 mg/m\^2 by vein daily for 24 hours for courses 1, 3, 5, 7.
Study NCT00038610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: 10 mcg/kg/day after completion of chemotherapy until neutrophil recovery to 1 x 109/L or higher for all courses.
Study NCT03655002 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cytokine-based Biologic Agent IRX-2
Description: Given SC
Study NCT03655002 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT04559529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV) 500 mg
Description: The levetiracetam pill will look just like the placebo pill.
Study NCT04559529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo pill will look just like the levetiracetam pill, but does not contain any levetiracetam.
Study NCT02967380 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Description: Undergo DCE-MRI
Study NCT02967380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobenate Dimeglumine
Description: Given IV
Study NCT02967380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobutrol
Description: Given IV
Study NCT02967380 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Gadopentetate Dimeglumine
Description: Given IV
Study NCT02723487 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.125%
Description: Patients will receive bilateral Transversus Abdominis Plane Block guided by ultrasound device using bupivacaine (Marcaine, 0.125%), 0.5 ml/kg on each side.
Study NCT02723487 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.25%
Description: Patients will receive bilateral Transversus Abdominis Plane Block guided by ultrasound device using bupivacaine (Marcaine, 0.25%), 0.5 ml/kg on each side.
Study NCT01153776 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 64-slice CT angiography
Description: the sensitivity and specificity of 64-slice CT angiography for the detection of lesions at the ostia and proximal segments of the reimplanted coronary arteries
Study NCT00548405 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alemtuzumab 12 mg
Description: Alemtuzumab 12 milligram (mg) per day intravenous (IV) infusion on 5 consecutive days at Month 0, followed by alemtuzumab 12 mg per day IV infusion on 3 consecutive days at Month 12.
Study NCT00548405 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alemtuzumab 24 mg
Description: Alemtuzumab 24 mg per day IV infusion on 5 consecutive days at Month 0, followed by alemtuzumab 24 mg per day IV infusion on 3 consecutive days at Month 12.
Study NCT00548405 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Interferon beta-1a
Description: Interferon beta-1a 44 microgram (mcg) subcutaneously 3-times weekly for 24 months. Dose adjustment was done as per Investigator's discretion.
Study NCT03462901 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous intramedullary fixation of displaced midshaft clavicular fractures .
Description: A group of 15 patients admitted to Assiut university with midshaft clavicular fractures treated by operative fixation of the fracture by single elastic rod through medial approach under image intensifier
Study NCT00268580 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Asthma Care Pathway
Description: Asthma care provided using standardized asthma care pathway
Study NCT04607278 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Oral probiotic supplementation was provided by iHealth; Cromwell, USA. Each sachet included a 1×1010 CFUs dose of four viable microbial cell preparation strains: there are two strains of lactobacillus genus (Lactobacillus acidophillus L1 (2.9×109) and Lactobacillus rhamnosus liobif (2.9×109)), Bifidobacterium longum (2.9×109) and Saccharomyces boulardii (1.3×109). Each participant took a total daily dose of 4×1010 CFUs.
Study NCT04607278 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Prebiotic
Description: The prebiotic was made up of inulin from the chicory plant and provided by the Fibrelle (Belgium) company. Five grams packs were given to the participants in boxes. Each participant was requested to take a total daily 10 g dose.
Study NCT04607278 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: It was composed of maltodextrin, and provided by the manufacturer Fibrelle; (Belgium). The prescription was similar to probiotics or prebiotics groups.
Study NCT02004639 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Masticators sparing techniques
Study NCT02004639 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: electro-acupunture treatment
Description: electro-acupunture treatment and sham-EA
Study NCT02004639 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: electro-acupunture treatment
Description: electro-acupunture treatment and sham-EA
Study NCT04506762 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Regional analgesia
Description: Insertion of bilateral ESP catheters
Study NCT00911378 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pressure support ventilation
Description: These patients are weaned by gradual reduction of pressure support and extubated when they tolerate a pressure support of 7 cm of water for one hour.
Study NCT00911378 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spontaneous breathing trials
Description: These patients are weaned by giving a T piece trial with 8 cm of water pressure support and extubated when they tolerate it for one hour.
Study NCT00005646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 150 mg/sq m IV over 3 hours weekly for 6 weeks per cycle
Study NCT02217527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active JNJ Drug
Description: 200 mg/day (100 mg b.i.d.) of Active JNJ Drug will be used for one week while attempting to briefly quit smoking on Mon-Fri of that week.
Study NCT02217527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo pill
Description: Placebo pill will be taken daily to assess ability to briefly quit smoking on Mon-Fri for one week.
Study NCT00002642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 50 mg/m2, IV Days 1 and 8, two 28 day cycles prior to surgery and two 28 day cycles after surgery
Study NCT00002642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: 50 mg/m2, IV Days 1-5, two 28 day cycles prior to surgery and two 28 day cycles after surgery
Study NCT00002642 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: surgery some time between weeks 9 and 12
Study NCT02333032 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inclined treadmill training
Study NCT03101345 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Peptamen® 1.5 vanilla
Description: Administration orally
Study NCT00088855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given IV
Study NCT00088855 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00002642 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET cobalt-60 gamma ray therapy
Description: 180 cGy per day, Days 1-5, weekly for 5 weeks
Study NCT01433276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperosmolar sodium lactate
Description: 1st loading : Upto 2 liters of Ringer's lactate, followed by Totilac which was given 5 mL/kgBW/15 minutes, followed by maintenance 2 mL/kgBW/hour for 3 hours
Study NCT01433276 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer's lactate
Description: 1st loading : Upto 2 litres of Ringer's lactate, followed by 5 mL/kgBW/15 minutes,followed by maintenance : 2 mL/kgBW/hour for 3 hours
Study NCT02621840 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mandatory On-Site Pre-Admission Testing
Study NCT04967040 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: medial plantar artery flap
Description: Medial plantar artery flap is a fasciocutaneous island flap raised from the non-weightbearing instep of the plantar foot. The dominant vascular pedicle of the flap consists of the medial plantar artery and venae comitantes
Study NCT04967040 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Distally based sural artery flap
Description: Distally based sural artery flap is a fascio-cutaneous island flap taken from the posterior aspect of the middle third of the leg and fed by the lower peroneal septo-cutaneous perforators in reverse fashion. Its vascular basis is the close association between the median superficial sural artery and peroneal artery perforators